Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis(315 views) Cirioni O, Ghiselli R, Orlando F, Silvestri C, De Luca S, Salzano AM, Mocchegiani F, Saba V, Scalise G, Scaloni A, Giacometti A
Critical Care Medicine (ISSN: 0090-3493), 2008 Sep; 36(9): 2629-2633.
Institute of Infectious Diseases and Public Health, Università Politecnica Delle Marche, Ancona, Italy
Department of General Surgery, I.N.R.C.A. I.R.R.C.S., Università Politecnica Delle Marche, Ancona, Italy
Experimental Animal Models for Aging Units, Research Department, I.N.R.C.A. I.R.R.C.S., Ancona, Italy
Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy
Proteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, Naples, Italy
References: Diekema, D.J., Pfaller, M.A., Jones, R.N., Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997 (1999) Clin Infect Dis, 29, pp. 595-60
Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care (2001) Crit Care Med, 29, pp. 1303-1310
Edgeworth, J.D., Treacher, D.F., Eykyn, S.J., A 25-year study of nosocomial bacteremia in an adult intensive care unit (1999) Crit Care Med, 27, pp. 1421-1428
Fowler Jr, V.G., Sakoulas, G., McIntyre, L.M., Persistent bacteremia due to methicillin- resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein (2004) J Infect Dis, 90, pp. 1140-1149
Ramphal, R., Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens (2004) Clin Infect Dis, 39, pp. S25-S31
Riedemann, N.C., Guo, R.F., Ward, P.A., Novel strategies for the treatment of sepsis (2003) Nature Med, 9, pp. 517-524
Cormican, M.G., Jones, R.N., Emerging resistance to antimicrobial agents in grampositive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci (1996) Drugs, 1, pp. S6-S12
Appelbaum, P.C., The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (2006) Clin Microbiol Infect, 1, pp. S16-S23
Hancock, R.E.W., Scott, M.G., The role of antimicrobial peptides in animal defenses (2000) Proc Natl Acad Sci USA, 97, pp. 8856-8861
Bevins, C.L., Zasloff, M., Peptides from frog skin (1990) Ann Rev Biochem, 59, pp. 395-414
Cannon, M., A family of wound healers (1987) Nature, 328, p. 478
Hancock, R.E.W., Cationic peptides: Effectors in innate immunity and novel antimicrobials (2001) Lancet Infect Dis, 1, pp. 156-164
Zasloff, M., Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor (1987) Proc Natl Acad Sci USA, 84, pp. 5449-5453
Doyle, J., Brinkworth, C.S., Wegener, K.L., nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications. The solution structure of a modified citropin 1.1 (2003) Eur J Biochem, 270, pp. 1141-1153
Batista, C.V., Scaloni, A., Rigden, D.J., A novel heterodimeric antimicrobial peptide from the tree-frog Phyllomedusa distincta (2001) FEBS Lett, 494, pp. 85-89
Raimondo, D., Andreotti, G., Saint, N., A folding-dependent mechanism of antimicrobial peptide resistance to degradation unveiled by solution structure of distinctin (2005) Proc Natl Acad Sci USA, 102, pp. 6309-6314
Sheppard, R.C., Williams, B.J., Acid-labile resin linkage agents for use in solid-phase peptidesynthesis (1982) Int J Peptide Protein Res, 20, pp. 451-454
(2003) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6, , Clinical and Laboratory Standards Institute CLSI, Villanova, PA, NCCLS
Eliopoulos, G.M., Moellering Jr, R.C., Antimicrobial combinations (1996) Antibiotics in Laboratory Medicine, pp. 330-393. , Lorian V Ed, Baltimore, MD, Williams and Wilkins
Craig, W.A., Redington, J., Ebert, S.C., Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections (1991) J Antimicrob Chemother, 27 (SUPPL. C), pp. 29-40
Opal, S.M., Cross, A.S., The use of immunocompromised animals as models for human septic shock (2005) Shock, 24, pp. S64-S70
Esmon, C.T., Why do animal models (sometimes) fail to mimic human sepsis? (2003) Crit Care Med, 31, pp. S219-S222
Bowdish, D.M.E., Davidson, D.J., Scott, M.G., Immunomodulatory activities of small host defense peptides (2005) Antimicrob Agents Chemother, 49, pp. 1727-1732
Hancock, R.E.W., Sahl, H.G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies (2006) Nat Biotechnol, 24, pp. 1551-1557
Zasloff, M., Antimicrobial peptides of multicellular organisms (2002) Nature, 415, pp. 389-395
Cirioni, O., Silvestri, C., Ghiselli, R., Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides (2006) Peptides, 27, pp. 2600-2606
Diekema, D. J., Pfaller, M. A., Jones, R. N., Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997 (1999) Clin Infect Dis, 29, pp. 595-60
Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care (2001) Crit Care Med, 29, pp. 1303-1310
Edgeworth, J. D., Treacher, D. F., Eykyn, S. J., A 25-year study of nosocomial bacteremia in an adult intensive care unit (1999) Crit Care Med, 27, pp. 1421-1428
Fowler Jr, V. G., Sakoulas, G., McIntyre, L. M., Persistent bacteremia due to methicillin- resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein (2004) J Infect Dis, 90, pp. 1140-1149
Riedemann, N. C., Guo, R. F., Ward, P. A., Novel strategies for the treatment of sepsis (2003) Nature Med, 9, pp. 517-524
Cormican, M. G., Jones, R. N., Emerging resistance to antimicrobial agents in grampositive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci (1996) Drugs, 1, pp. S6-S12
Appelbaum, P. C., The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (2006) Clin Microbiol Infect, 1, pp. S16-S23
Hancock, R. E. W., Scott, M. G., The role of antimicrobial peptides in animal defenses (2000) Proc Natl Acad Sci USA, 97, pp. 8856-8861
Bevins, C. L., Zasloff, M., Peptides from frog skin (1990) Ann Rev Biochem, 59, pp. 395-414
Batista, C. V., Scaloni, A., Rigden, D. J., A novel heterodimeric antimicrobial peptide from the tree-frog Phyllomedusa distincta (2001) FEBS Lett, 494, pp. 85-89
Sheppard, R. C., Williams, B. J., Acid-labile resin linkage agents for use in solid-phase peptidesynthesis (1982) Int J Peptide Protein Res, 20, pp. 451-454
(2003) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6, , Clinical and Laboratory Standards Institute CLSI, Villanova, PA, NCCLS
Eliopoulos, G. M., Moellering Jr, R. C., Antimicrobial combinations (1996) Antibiotics in Laboratory Medicine, pp. 330-393. , Lorian V Ed, Baltimore, MD, Williams and Wilkins
Craig, W. A., Redington, J., Ebert, S. C., Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections (1991) J Antimicrob Chemother, 27 (SUPPL. C), pp. 29-40
Opal, S. M., Cross, A. S., The use of immunocompromised animals as models for human septic shock (2005) Shock, 24, pp. S64-S70
Esmon, C. T., Why do animal models (sometimes) fail to mimic human sepsis? (2003) Crit Care Med, 31, pp. S219-S222
Bowdish, D. M. E., Davidson, D. J., Scott, M. G., Immunomodulatory activities of small host defense peptides (2005) Antimicrob Agents Chemother, 49, pp. 1727-1732
Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis
Objective: To investigate the efficacy of distinctin in a neutropenic mouse model of staphylococcal sepsis. Design: Prospective, randomized, and controlled animal study. Setting: Research laboratory in a University Hospital. Subjects: BALB/c male mice. Interventions: Mice were rendered neutropenic by injecting cyclophosphamide (200 mg/kg of body weight/day) on days -4 and -2 preinfection. Infection was induced at time 0 by intraperitoneal injection of 1 x 10(9) colony forming units of the staphylococcal strain. For each model, all animals were randomized to receive intravenous isotonic sodium chloride solution, 1 mg/kg distinctin, and 10 mg/kg imipenem, 10 mg/kg vancomycin, 10 mg/kg teicoplanin or 10 mg/kg linezolid alone, or combined with 1 mg/kg distinctin. Measurements and Main Results: Lethality, bacterial growth in blood and peritoneum, spleen, liver, and mesenteric lymph nodes. Results: All combined regimen showed lower lethality rates than singly treated-groups. Distinctin plus vancomycin or teicoplanin exerted the lowest lethality rate. All regimens were significantly superior to controls at reducing blood, spleen, peritoneum, liver and mesenteric lymph node complex bacterial burdens, whereas all combined treated groups were higher effective than singly treated groups. Conclusion: Our data indicate that distinctin alone or combined with other antibiotics may be useful in treating severe staphylococcal infections.
Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote